Journals / Turkish Journal of Endocrinology and Metabolism / 2021 / Cilt: 25 - Sayı: 2

A Case of Plurihormonal Pituitary GiantMacroadenoma

Plurihormonal Hipofizer Dev Makroadenomu Olan Olgu Sunumu

Pages
227–231
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to this condition, we should perform a complete biochemical and histologic evaluation in patients with pituitary adenomas

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We would like to draw the attention of the readers to Pit-1positive giant macroadenomas in this work.
📊
Key Findings & Data:A 62-year-old male patient was admitted to the hospital due to his vision loss and blurred vision in the left eye.
💡
Conclusion & Impact:According to this condition, we should perform a complete biochemical and histologic evaluation in patients with pituitary adenomas
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

We would like to draw the attention of the readers to Pit-1positive giant macroadenomas in this work. A 62-year-old male patient was admitted to the hospital due to his vision loss and blurred vision in the left eye. His pituitary magne-tic resonance imaging revealed the presence of a diffuse and homogeneous mass lesion originating from the pitui-tary gland having grade 4 invasion into the bilateral caver-nous sinus and eroding the base of the sella. He consulted our department before his operation in 2016. Laboratory examination revealed that pituitary hormone levels were within normal ranges while the testosterone level [total tes-tosterone 0.27 ng/mL (2.8-8)] was low. Pathological fin-dings revealed a pituitary adenoma that displayed focal immunoreactivity to thyrotrophin, growth hormone, and prolactin. While the main prevalence and the basic mecha-nism of plurihormonal pituitary adenomas are not clear, one of the hypotheses is based on the role of divergent trans-cription factors such as Pit-1. According to this condition, we should perform a complete biochemical and histologic evaluation in patients with pituitary adenomas

Özet

Bu çalışmada, Pit-1 pozitif dev makroadenomlara dikkatçekmek istedik. Altmış iki yaşında erkek hasta, sol gözdegörmede azalma ve bulanık görme nedeniyle hastaneyebaşvurdu. Hipofiz manyetik rezonans görüntülemesinde, hi- pofiz bezinden kaynaklanan yaygın homojen kitle lezyonu- nun, bilateral kavernöz sinüse 4. derece invazyonunun olduğu ve sella tabanını aşındırdığı izlendi. Preoperatif dö- nemde, endokrinoloji bölümümüze konsülte edilmişti. La- boratuvar incelemesinde hipofiz hormon düzeyleri normal sınırlarda, total testosteron düzeyi 0,27 ng/mL (2,8-8) dü- şüktü. Operasyon sonrası patoloji sonucu, fokal tirotropin,büyüme hormonu ve prolaktin immünoreaktivitesi gösteren bir hipofiz adenoma olarak raporlandı. Plurihormonal hipo- fiz adenomlarının prevalansı ve temel mekanizması net de- ğildir; hipotezlerden biri, Pit-1 gibi farklı transkripsiyonfaktörlerinin rolüne bağlı olabileceği yönündedir. Hipofizadenomlu hastalarda, tam bir biyokimyasal ve histolojik de-ğerlendirme yapmalıyız.

🔖

Cite This Article

SAYGILI, F., ÖZGİRAY, E., ERTAN, Y., ÖZIŞIK, H., ERASLAN, C., YÜREKLİ, B. S. (2022). A Case of Plurihormonal Pituitary GiantMacroadenoma. Turkish Journal of Endocrinology and Metabolism, Cilt: 25 - Sayı: 2, 227–231. https://ajindex.com/articles/605339

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Mete O, Lopes MB. Overview of the 2017 WHO Clas- sification of Pituitary Tumors. Endocr Pathol. 2017;28:228-243. [Crossref] [Pubmed] 2. Ho DM, Hsu CY, Ting LT, Chiang H. Plurihormonal pi- tuitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification. Hi- stopathology. 2001;39:310-319. [Crossref] [Pub- med] 3. Osamura RY, Tahara S, Kurotani R, Sanno N, Mat- suno A, Teramoto A. Contributions of immunohis- tochemistry and in situ hybridization to the functional analysis of pituitary adenomas. J Histoc- hem Cytochem. 2000;48:445-458. [Crossref] [Pubmed] 4. Roche C, Rasolonjanahary R, Thirion S, Goddard I, Fusco A, Figarella-Branger D, Dufour H, Brue T, Franc JL, Enjalbert A, Barlier A. Inactivation of transcription factor pit-1 to target tumoral somato- lactotroph cells. Hum Gene Ther. 2012;23:104-114. [Crossref] [Pubmed] 5. Kontogeorgos G KK, Lloyd RV, Righi A. Plurihormo- nal and double adenomas. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J, eds. World Health Organiza- tion Classification of Tumours of Endocrine Organs (4th ed). Lyon; IARC Press; 2017:39-40. [Link] 6. Rasul FT, Jaunmuktane Z, Khan AA, Phadke R, Po- well M. Plurihormonal pituitary adenoma with con- comitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature. Acta Neurochir (Wien). 2014;156:141-146. [Crossref] [Pubmed] 7. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134:521-535. [Crossref] [Pubmed] 8. Horvath E, Kovacs K, Smyth HS, Cusimano M, Sin- ger W. Silent adenoma subtype 3 of the pituitary- immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pat- hol. 2005;29:511-524. [Crossref] [Pubmed] 9. Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf). 2009;71:92-99. [Crossref] [Pubmed] 10. Pellegrini I, Barlier A, Gunz G, Figarella-Branger D, Enjalbert A, Grisoli F, Jaquet P. Pit-1 gene expres- sion in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab. 1994;79:189-196. [Cros- sref] [Pubmed] 11. Yamada S, Takahashi M, Hara M, Hattori A, Sano T, Ozawa Y, Shishiba Y, Hirata K, Usui M. Pit-1 gene expression in human pituitary adenomas using the reverse transcription polymerase chain reaction method. Clin End